ATE530196T1 - Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung - Google Patents

Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung

Info

Publication number
ATE530196T1
ATE530196T1 AT05780195T AT05780195T ATE530196T1 AT E530196 T1 ATE530196 T1 AT E530196T1 AT 05780195 T AT05780195 T AT 05780195T AT 05780195 T AT05780195 T AT 05780195T AT E530196 T1 ATE530196 T1 AT E530196T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
neutralizing monoclonal
anthrax toxin
toxin neutralizing
human anthrax
Prior art date
Application number
AT05780195T
Other languages
English (en)
Inventor
Herman Groen
Christine Cool-Kebbedies
Kunja Slopsema
Hans Westra
Original Assignee
Iq Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iq Therapeutics Bv filed Critical Iq Therapeutics Bv
Application granted granted Critical
Publication of ATE530196T1 publication Critical patent/ATE530196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1278—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
AT05780195T 2004-03-03 2005-03-03 Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung ATE530196T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54964104P 2004-03-03 2004-03-03
PCT/IB2005/002495 WO2005120567A2 (en) 2004-03-03 2005-03-03 Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE530196T1 true ATE530196T1 (de) 2011-11-15

Family

ID=35276110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05780195T ATE530196T1 (de) 2004-03-03 2005-03-03 Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung

Country Status (7)

Country Link
US (2) US7658925B2 (de)
EP (2) EP2163257A1 (de)
AT (1) ATE530196T1 (de)
AU (1) AU2005251535A1 (de)
CA (1) CA2560759A1 (de)
ES (1) ES2376337T3 (de)
WO (1) WO2005120567A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60128008T2 (de) * 2000-12-05 2008-01-10 Wisconsin Alumni Research Foundation, Madison Rezeptor für ein toxin aus bacillus anthracis
WO2004052277A2 (en) * 2002-12-05 2004-06-24 Wisconsin Alumni Research Foundation Anthrax antitoxins
WO2005026375A2 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
US20060246079A1 (en) 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
US7658925B2 (en) * 2004-03-03 2010-02-09 Iq Therapeutics Bv Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
US7838252B2 (en) * 2005-02-17 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject having an anthrax toxin mediated condition
KR100694508B1 (ko) * 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
CA2616859C (en) 2005-08-03 2015-04-14 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
EP1981535A2 (de) * 2005-12-22 2008-10-22 IQ Corporation Zusammensetzungen und verfahren zur modulierung der immunantwort
US20090280130A1 (en) * 2006-06-14 2009-11-12 Children's Medical Center Corporation Method for the treatment of anthrax toxicity
GB0612456D0 (en) * 2006-06-23 2007-03-28 Secr Defence Antibody for anthrax
CN101636157A (zh) * 2007-01-12 2010-01-27 康乃尔研究基金会有限公司 作为抗菌干预的新型靶的腺苷酰环化酶
US9095578B2 (en) * 2007-01-12 2015-08-04 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens
EP2463304B1 (de) * 2007-02-23 2014-04-30 The United States of America as represented by the Secretary, Department of Health and Human Services Monoklonale Antikörper zur Neutralisierung von Anthrax-Toxinen
KR100868248B1 (ko) 2007-03-13 2008-11-12 한양대학교 산학협력단 탄저 감염 진단용 신규한 펩타이드 탐침
WO2009009759A2 (en) 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
GB0809474D0 (en) * 2008-05-27 2008-07-02 Prendergast Patrick T Comosition and method for teh assay and treatment of anthrax
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
US8343495B2 (en) * 2009-01-10 2013-01-01 Auburn University Equine antibodies against Bacillus anthracis for passive immunization and treatment
WO2010082134A1 (en) * 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
US20110129460A1 (en) * 2009-01-14 2011-06-02 IQ Therapeutics B.V. Combination Antibodies For The Treatment And Prevention Of Disease Caused By Bacillus Anthracis And Related Bacteria And Their Toxins
EP2483307A1 (de) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren
GB2480298A (en) * 2010-05-13 2011-11-16 Secr Defence Antibodies against Bacillus anthracis
WO2018210896A1 (en) * 2017-05-19 2018-11-22 F. Hoffmann-La Roche Ag Method for the production of thymocyte supernatant

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
EP1189931B1 (de) * 1999-07-02 2006-06-21 Genentech, Inc. An her2 bindende peptidverbindungen
AU2002254482A1 (en) * 2001-03-19 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
US7262019B2 (en) * 2001-05-03 2007-08-28 Immunetics, Inc. System and methods for detection of Bacillus anthracis related analytes in biological fluids
GB0126266D0 (en) * 2001-11-01 2002-01-02 Microbiological Res Authority Anthrax antigenic compositions
US20040009178A1 (en) 2002-02-11 2004-01-15 Bowdish Katherine S. Immunotherapeutics for biodefense
US20040258699A1 (en) * 2002-02-11 2004-12-23 Bowdish Katherine S. Immunotherapeutics for biodefense
AU2004270103B2 (en) 2003-05-21 2012-02-23 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies against Bacillusanthracis protective antigen
AU2003304600A1 (en) * 2003-11-14 2005-06-29 Avanir Pharmaceuticals Neutralizing human antibodies to anthrax toxin generated by recall technology
WO2005081749A2 (en) 2004-01-23 2005-09-09 Avanir Pharmaceuticals, Inc. Neutralizing human antibodies to anthraxtoxin
US7658925B2 (en) * 2004-03-03 2010-02-09 Iq Therapeutics Bv Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP2163257A1 (de) 2010-03-17
US20060258842A1 (en) 2006-11-16
EP1729806B1 (de) 2011-10-26
CA2560759A1 (en) 2005-12-22
US20110059098A1 (en) 2011-03-10
EP1729806A2 (de) 2006-12-13
US7658925B2 (en) 2010-02-09
ES2376337T3 (es) 2012-03-13
WO2005120567A2 (en) 2005-12-22
WO2005120567A3 (en) 2006-03-30
AU2005251535A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
ATE530196T1 (de) Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung
MX2021015024A (es) Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
DE60142410D1 (de) Immunomodulatorische polynukleotide und verfahren zur deren verwendung
ATE544772T1 (de) Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür
DE60231601D1 (de) Einrichtung und verfahren zur behandlung
DE602004012364D1 (de) Zielführungsvorrichtung, System und Verfahren
TW200618810A (en) Treatment of respiratory syncytial virus (RSV) infection
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
ATE423571T1 (de) Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
DE60217597D1 (de) Gerät und Verfahren zur Personenerkennung
DE60135251D1 (de) Trokar-zugvorrichtung und verfahren
CY1110188T1 (el) Αντισωματα κατα συζυγων φωσφορυλχολινης
ATE485057T1 (de) Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
DE60307890D1 (de) Steuerung für sterilisationsvorrichtung und verfahren
FR2854053B1 (fr) Dispositif et methode de traitement transuretral de la prostate
DE602006007808D1 (de) Vorrichtung, verfahren und verwendung zur behandlung von neuropathie mit stickoxid
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
EP2394658A3 (de) Passive Immunisierung gegen Clostridium difficile-Erkrankung
DE60234674D1 (de) Verfahren, Program und Gerät zur Authentifizierung
ATE440508T1 (de) Verfahren zur behandlung und/oder vorbeugung von infektionen bei kleinkindern, die über kaiserschnitt geboren werden
DE602004015456D1 (de) Patiententemperatur-wiederholungssystem und verfahren
DE602005011305D1 (de) System und verfahren zur steuerung von sprengarbeiten
WO2009154995A3 (en) Interleukin 10 receptor (il-10r) antibodies and methods of use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties